email article
For heart attack survivors with left ventricular dysfunction, sacubitril/valsartan (Entresto) was no better than ramipril at reducing heart failure (HF) events in the strictest sense in the PARADISE-MI trial, but several signals nevertheless pointed to potential benefit in some patients.
Acute MI patients shared similar rates of the primary outcome cardiovascular death, HF hospitalization, or outpatient development of HF over a median 23 months whether they had been randomized to sacubitril/valsartan or the angiotensin-converting enzyme (ACE) inhibitor (11.9% vs 13.2%, HR 0.90, 95% CI 0.78-1.04), according to Marc Pfeffer, MD, PhD, of Brigham and Women s Hospital and Harvard Medical School in Boston.
ACC, Novo Nordisk launch program to improve type 2 diabetes care
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Endovascular Approach to Diabetic Limb Ischemia Tied to Lower Hospital Mortality, More Amputations
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.